“I am delighted that we have signed this agreement with a global leader in personal care. Hygiene and personal care has become increasingly important to consumers and the market opportunity for effective antimicrobials is growing,” said Stephen Jones CEO of Syntopix.
The agreement builds upon Syntopix’s key strategies and will help to form partnerships with leading healthcare and cosmetics companies to develop those products through to market.
“It validates our strategy that identifying and developing compounds that have antimicrobial properties and combining this with an understanding of consumer need is of great value to global consumer healthcare companies,” Jones told CosmeticsDesign-Europe.com.
The drug discovery company currently has a compound under clinical evaluation, and rights of first refusal to negotiate further development and eventual commercialisation of this compound has been granted to the partner company, under terms of the agreement.
Customer preference for antimicrobial products
With increasing interest in antimicrobials, current developments centre on compounds that can benefit in the treatment of acne, gingivitis, and body odour, Syntopix explained to CosmeticsDesign-Europe.com.
“Syntopix intends to capitalize on this consumer need,” Jones added.
Antimicrobials play an important role in ensuring personal care products are free of micro-organisms during storage and once opened. Consumer preference for antibacterial products has lead to them being easily accessible over the counter.
In addition to these products and compounds, antimicrobial nanotechnology is being introduced as a mechanical method to eliminate microbes, without risk of genetic adaptation. Syntopix will not be looking to expand into this area at present.